
Jean-Christophe Pignon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7002158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4045-4055.	7.0	12
2	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunology Research, 2021, 9, 156-169.	3.4	56
3	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	7.0	49
4	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	7.0	154
5	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	30.7	488
6	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade Journal of Clinical Oncology, 2020, 38, 5010-5010.	1.6	2
7	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial Journal of Clinical Oncology, 2020, 38, 5023-5023.	1.6	6
8	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	7.0	80
9	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC) Journal of Clinical Oncology, 2019, 37, 4568-4568.	1.6	4
10	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genetics, 2018, 14, e1007679.	3.5	14
11	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST Journal of Clinical Oncology, 2018, 36, 619-619.	1.6	2
12	p63+ ureteric bud tip cells are progenitors of intercalated cells. JCI Insight, 2017, 2, .	5.0	14
13	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression Journal of Clinical Oncology, 2017, 35, 4573-4573.	1.6	1
14	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8 ⁺ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC) Journal of Clinical Oncology, 2017, 35, 477-477.	1.6	9
15	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.	1.8	19
16	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2) Journal of Clinical Oncology, 2017, 35, 4576-4576.	1.6	0
17	Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics, 2016, 48, 725-732.	21.4	288
18	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma, Clinical Cancer Research, 2016, 22, 2445-2452.	7.0	193

#	Article	IF	CITATIONS
19	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor <scp>STAT3</scp> . Cancer Cytopathology, 2015, 123, 696-706.	2.4	11
20	Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate. PLoS ONE, 2015, 10, e0128489.	2.5	7
21	ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Human Pathology, 2015, 46, 384-389.	2.0	13
22	p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8105-8110.	7.1	185